NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Horizon Blue Cross Blue Shield of New Jersey for its Veristrat test.

Horizon BCBS of New Jersey, which covers 3.8 million people in that state, determined as of May 10, 2016 that the test was a medically necessary benefit for patients with non-small cell lung cancer. With the decision, Veristrat is now covered for roughly 205 million people in the US, Biodesix said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.